Addex Therapeutics Ltd (ADXN) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.130x

Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.130x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-619.94K ≈ $-783.77K USD) by net assets (CHF4.76 Million ≈ $6.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ADXN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Addex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
mTouche Technology Bhd KLSE:0092	-0.178x
NB Private Equity Partners Ltd LSE:NBPE	0.101x
Multi Ways Holdings Ltd NYSE MKT:MWG	0.214x
SUNation Energy Inc. NASDAQ:SUNE	0.110x
Openlearning Ltd AU:OLL	0.356x
Destiny Media Technologies Inc V:DSY	-0.110x
DTI Group Ltd AU:DTI	-0.075x
Sundaram Multi Pap Limited NSE:SUNDARAM	-0.097x

Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2025)

The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Addex Therapeutics Ltd market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CHF4.76 Million ≈ $6.02 Million	CHF-2.17 Million ≈ $-2.75 Million	-0.456x	+17.85%
2024-12-31	CHF9.67 Million ≈ $12.23 Million	CHF-5.37 Million ≈ $-6.79 Million	-0.556x	+92.04%
2023-12-31	CHF1.15 Million ≈ $1.45 Million	CHF-7.99 Million ≈ $-10.10 Million	-6.977x	-108.55%
2022-12-31	CHF4.91 Million ≈ $6.21 Million	CHF-16.44 Million ≈ $-20.78 Million	-3.346x	-285.22%
2021-12-31	CHF16.93 Million ≈ $21.41 Million	CHF-14.71 Million ≈ $-18.59 Million	-0.869x	-4.18%
2020-12-31	CHF14.61 Million ≈ $18.47 Million	CHF-12.18 Million ≈ $-15.40 Million	-0.834x	-124.41%
2019-12-31	CHF25.52 Million ≈ $32.27 Million	CHF-9.48 Million ≈ $-11.99 Million	-0.372x	-932.20%
2018-12-31	CHF39.24 Million ≈ $49.61 Million	CHF1.75 Million ≈ $2.21 Million	0.045x	+102.81%
2017-12-31	CHF1.34 Million ≈ $1.70 Million	CHF-2.13 Million ≈ $-2.70 Million	-1.590x	+87.10%
2016-12-31	CHF218.59K ≈ $276.36K	CHF-2.69 Million ≈ $-3.41 Million	-12.326x	-680.44%
2015-12-31	CHF1.66 Million ≈ $2.10 Million	CHF-2.63 Million ≈ $-3.32 Million	-1.579x	-105.86%
2014-12-31	CHF2.35 Million ≈ $2.97 Million	CHF-1.80 Million ≈ $-2.28 Million	-0.767x	+85.28%
2013-12-31	CHF3.03 Million ≈ $3.83 Million	CHF-15.78 Million ≈ $-19.95 Million	-5.214x	-188.38%
2012-12-31	CHF16.29 Million ≈ $20.60 Million	CHF-29.45 Million ≈ $-37.24 Million	-1.808x	-130.40%
2011-12-31	CHF33.84 Million ≈ $42.78 Million	CHF-26.55 Million ≈ $-33.57 Million	-0.785x	-61.27%
2010-12-31	CHF64.41 Million ≈ $81.44 Million	CHF-31.34 Million ≈ $-39.62 Million	-0.487x	+4.14%
2009-12-31	CHF77.58 Million ≈ $98.08 Million	CHF-39.38 Million ≈ $-49.78 Million	-0.508x	-239.45%
2008-12-31	CHF118.99 Million ≈ $150.44 Million	CHF-17.79 Million ≈ $-22.49 Million	-0.150x	+36.53%
2007-12-31	CHF140.11 Million ≈ $177.13 Million	CHF-33.00 Million ≈ $-41.73 Million	-0.236x	+49.08%
2006-12-31	CHF42.28 Million ≈ $53.45 Million	CHF-19.56 Million ≈ $-24.73 Million	-0.463x	--

About Addex Therapeutics Ltd

SW:ADXN Switzerland Biotechnology

Market Cap

$8.30 Million

CHF6.56 Million CHF

Market Cap Rank

#27865 Global

#211 in Switzerland

Share Price

CHF0.04

Change (1 day)

+1.37%

52-Week Range

CHF0.04 - CHF0.07

All Time High

CHF3.90